Full video transcriptClick to expand
Auto-generated transcript of @mariahhopkins_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I was a super responder on a GLP1 and I made a video last week talking about it and someone
- 0:03commented on it and said that the term super responder is unnecessary because it is not rare for someone
- 0:10to lose 15 to 30 in the first month on a GLP1. And to that I say it is rare. Unfortunately a lot
- 0:17of people go into their GLP1 experience and don't drop 15 to 30 in the first month and think that
- 0:23there's something wrong with them or they're doing something wrong when in the reality is most people
- 0:28are not losing that much the first month which is why I talk about being a super responder which is
- 0:33why we talk about being an average normal response and a slow responder and just understanding in general
- 0:39everyone is going to respond differently but no it is not normal for someone to respond
- 0:45and be down 15 to 30 in the first month on a GLP1. And I would never want someone going into their
- 0:51GLP1 experience expecting that because that's not the case for most people. Most people are only down
- 0:57about five maybe 10 the first month and if that's you there is nothing wrong with you you're not
- 1:03doing anything wrong that's very normal and that's a great response. I was down 22 the first month and
- 1:09it was so incredibly fast. I of course wasn't complaining at the time but I didn't know that that was really
- 1:16fast so to say that it is not rare it is rare and if there is one fact about GLP1s it's that everyone
- 1:25is going to respond differently and sometimes it doesn't mean that there's something wrong with you
- 1:29if you're responding slower than maybe the person next to you.
GLP-1 first month troubleshooting: what the science says
Quick answer
Clinical trial data from STEP 1 and SURMOUNT-1 show average first-month weight loss of approximately two to four percent of body weight on semaglutide or tirzepatide, meaning losses of 15 to 30 pounds in month one are statistically uncommon for most participants and qualify as outlier responses. Response variability is well-documented in the literature, driven by differences in drug type, starting metabolic profile, adherence, and dose titration schedules. Patients who experience slower early losses are not contraindicated for continued therapy and often achieve clinically meaningful reductions over a longer treatment window.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 first month troubleshooting: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 first month troubleshooting: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 first month troubleshooting: what the science says" from Mariah Hopkins. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Clinical trial data from STEP 1 and SURMOUNT-1 show average first-month weight loss of approximately two to four percent of body weight on semaglutide or tirzepatide, meaning losses of 15 to 30 pounds in month one are statistically uncommon for most participants and qualify as outlier responses.
The reason this review is not generic is the source wording and the canonical claim label "glp1 lots of troubleshoot goes into that first month for most peo." In this clip, the useful excerpt is: "I was a super responder on a GLP1 and I made a video last week talking about it and someone commented on it and said that the term super responder is unnecessary because it is not rare for someone to lose 15 to 30 in the first month on a..." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Clinical trial data from STEP 1 and SURMOUNT-1 show average first-month weight loss of approximately two to four percent of body weight on semaglutide or tirzepatide, meaning losses of 15 to 30 pounds in month one are statistically uncommon for most participants and qualify as outlier responses.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Clinical trial data from STEP 1 and SURMOUNT-1 show average first-month weight loss of approximately two to four percent of body weight on semaglutide or tirzepatide, meaning losses of 15 to 30 pounds in month one are statistically uncommon for most participants and qualify as outlier responses. Response variability is well-documented in the literature, driven by differences in drug type, starting metabolic profile, adherence, and dose titration schedules. Patients who experience slower early losses are not contraindicated for continued therapy and often achieve clinically meaningful reductions over a longer treatment window.
- STEP 1 trial data (Wilding et al., 2021, NEJM) show average semaglutide users lost roughly two to four percent of body weight in the first month, not 15 to 30 pounds.
- A 15 to 30-pound loss in month one would require losing half a pound to a pound per day, which is outside normal physiological fat-loss rates and likely involves significant water weight if it occurs.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- STEP 1 trial data (Wilding et al., 2021, NEJM) show average semaglutide users lost roughly two to four percent of body weight in the first month, not 15 to 30 pounds.
- A 15 to 30-pound loss in month one would require losing half a pound to a pound per day, which is outside normal physiological fat-loss rates and likely involves significant water weight if it occurs.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produces faster early losses than semaglutide alone, so expected first-month results differ depending on which medication you are prescribed.
- The terms super responder, average responder, and slow responder are community shorthand, not standardized clinical classifications recognized in GLP-1 research.
- Most GLP-1 trials show the largest proportion of total weight loss occurring between months three and twelve, meaning slow starters can still reach clinically significant outcomes.
- Individual factors including starting weight, metabolic rate, insulin resistance status, and dose titration pace all shape first-month response and make peer comparison an unreliable benchmark.
- Five to ten pounds lost in the first month is consistent with clinical trial averages and represents a real, meaningful response, not a failure.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @mariahhopkins_ actually say?
She pushed back on a commenter who claimed that losing 15 to 30 pounds in the first month on a GLP-1 is common. Her position: it is rare. She described herself as a "super responder," said she lost 22 pounds in her first month, and argued that most people lose closer to five to ten pounds in month one. She also made the broader point that individual response varies widely, and that slower losers are not doing anything wrong.
This is a community-education framing, not a medical claim. She is not prescribing anything or promising outcomes. She is trying to calibrate expectations, which is a reasonable thing to do in a space where viral weight-loss results routinely set unrealistic benchmarks for newcomers.
Does the science back this up?
Mostly, yes. Clinical trial data consistently shows that average weight loss in the first month of GLP-1 therapy is modest, not dramatic. Losing 15 to 30 pounds in 30 days would be extraordinary by any standard in the published literature.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) tested semaglutide 2.4 mg weekly in adults with obesity. At week four, mean weight loss was roughly 2 to 4 percent of body weight. For a 200-pound person, that is four to eight pounds, not 15 to 30. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed similar early-phase results with tirzepatide. First-month losses in these trials were real but unspectacular on average.
It is worth noting that early losses in real-world settings can be higher than trial averages due to starting water weight, dietary changes, and nausea-related reduced intake. But 22 pounds in one month is still an outlier, not a benchmark. Calling it rare is not an overstatement.
What did they get wrong (or right)?
She got the core claim right. The idea that "super responder" is an unnecessary label because 15 to 30 pounds in month one is common is not supported by clinical data. She is correct to push back on it.
Where things get slightly fuzzy is the informal terminology. "Super responder," "average responder," and "slow responder" are not standardized clinical classifications in GLP-1 research. They are community shorthand. That is fine for social media, but worth knowing if you are using these categories to interpret your own results. The actual variability in response is documented, but the cutoffs she implies (five to ten pounds being typical, 15-plus being rare) are reasonable estimates, not derived from a single authoritative source.
She also does not distinguish between GLP-1 medications. Tirzepatide, which acts on both GLP-1 and GIP receptors, tends to produce faster and larger early losses than semaglutide alone in head-to-head comparisons (Frías et al., 2021, New England Journal of Medicine). The drug you are on matters for calibrating expectations, and that nuance is missing here.
What should you actually know?
First-month weight loss on GLP-1 therapy is real but usually modest. If you are losing five to ten pounds in month one, that is consistent with what clinical trials show for most participants. If you are losing more than that, you are an outlier in a good way. If you are losing less, you are also within a normal range, especially in the first few weeks before reaching a therapeutic dose.
The more important signal is trajectory over time, not the first month. The STEP and SURMOUNT trials show that most meaningful weight loss accumulates over months three through twelve. People who lose slowly early can still reach significant total reductions. Expecting your results to mirror someone's viral TikTok month-one drop is one of the fastest ways to become discouraged unnecessarily.
Individual factors like starting weight, metabolic rate, insulin sensitivity, and which medication you are on all influence how quickly your body responds. A prescribing clinician can help you interpret your specific response in context, which is something no TikTok video, including this one, can do for you.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Mariah Hopkins · TikTok creator
147.4K views on this video
Lots of troubleshoot goes into that first month for most people so be patient with yourself 🥰 #glp1maintenance #glp1community #glp1tips
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about step 1 trial data (wilding et al., 2021, nejm) show?
STEP 1 trial data (Wilding et al., 2021, NEJM) show average semaglutide users lost roughly two to four percent of body weight in the first month, not 15 to 30 pounds.
What does the video say about a 15 to 30-pound loss in month one would require?
A 15 to 30-pound loss in month one would require losing half a pound to a pound per day, which is outside normal physiological fat-loss rates and likely involves significant water weight if it occurs.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide produces faster?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produces faster early losses than semaglutide alone, so expected first-month results differ depending on which medication you are prescribed.
What does the video say about the terms super responder, average responder,?
The terms super responder, average responder, and slow responder are community shorthand, not standardized clinical classifications recognized in GLP-1 research.
What does the video say about most glp-1 trials show the largest proportion of total weight?
Most GLP-1 trials show the largest proportion of total weight loss occurring between months three and twelve, meaning slow starters can still reach clinically significant outcomes.
What does the video say about individual factors including starting weight, metabolic rate, insulin resistance status,?
Individual factors including starting weight, metabolic rate, insulin resistance status, and dose titration pace all shape first-month response and make peer comparison an unreliable benchmark.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Mariah Hopkins, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.